Is Saxenda the same as Wegovy?

We spoke with Dr. Yael Cooperman, M.D. about Saxenda and Wegovy, the similarities between the medications, and the differences.

Saxenda and Wegovy are both part of the same class of medications typically prescribed to manage diabetes or obesity known as GLP-1 receptor agonists but they aren’t the same drug: Saxenda is a brand name of a drug called liraglutide while Wegovy is a brand name of a drug called semaglutide. 

While not all GLP-1 drugs are approved by the FDA for weight loss, both Saxenda and Wegovy are approved for this use. Both are injectable medications administered in increasing doses, meaning your healthcare provider will typically start you on a lower dose and slowly prescribe higher doses to maximize weight loss while minimizing side effects.

Also, while Wegovy is injected once a week, Saxenda is a daily injection, because Wegovy lasts longer in the bloodstream than Saxenda. 

While research has shown that Wegovy typically leads to more weight loss than Saxenda, Saxenda has been shown in trials to be more effective for managing blood sugar levels and also helps reduce the risk of heart attack and stroke, so it’s usually a better option than Wegovy for people with diabetes and a history of heart disease, heart attack, or stroke who are trying to lose weight. Also, medication availability may determine which drug you are prescribed by your healthcare provider.

---

How we reviewed this article

Every article on Health Guide goes through rigorous fact-checking by our team of medical reviewers. Our reviewers are trained medical professionals who ensure each article contains the most up-to-date information, and that medical details have been correctly interpreted by the writer.

Editorial Guidelines | Medical Review Process

Current version

August 16, 2023

Written by

Health Guide Team

Fact checked by

Yael Cooperman, MD

---

About the medical reviewer

Yael Cooperman, MD, Ro

Yael Cooperman is a physician and works as a Senior Manager, Medical Content & Education at Ro.